José G. Pérez Ramos, PhD, MPH, Adriana Garriga-López, PhD, and Carlos E. Rodríguez-Díaz, PhD, MPH
Hurricane María, earthquakes, the COVID-19 pandemic, and relentless privatization and fragmentation of the health care system have led to very poor health outcomes.
AMA J Ethics. 2022;24(4):E305-312. doi:
10.1001/amajethics.2022.305.
Long-acting injectables powerfully augment HIV care, but broad acceptance and uptake could be compromised by what we know about experiences with antipsychotics.
AMA J Ethics. 2021;23(5):E405-409. doi:
10.1001/amajethics.2021.405.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
COVID-19 underscores historical precedent for fear-driven responses that disregard autonomy among persons with low income who are also persons of color.
AMA J Ethics. 2021;23(11):E840-846. doi:
10.1001/amajethics.2021.840.